Therapeutic Drug Monitoring of Teicoplanin in Children

Shandong University500 enrolled

Overview

In this study, the therapeutic drug monitoring of teicoplanin is carried out among children to obtain the drug concentration, clinical efficacy and safety data of children patients in different gender and age groups. Then we analyze the relationship between blood drug concentration and efficacy and safety, and provide recommendations for the treatment window of teicoplanin in Chinese children.

Study Type

OBSERVATIONAL

Enrollment

500

Conditions

Bacterial Infections

Interventions

Teicoplanin-PMMADRUG

Therapeutic drug monitoring of teicoplanin

Eligibility

Sex: ALLMax age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Teicoplanin was administered intravenously; * Teicoplanin was used for therapeutic purposes; * Age:≤18 years; * Clinician confirms and plans to diagnose the patient with gram-positive coccus infection; * Patients with therapeutic concentration monitoring of teicoplanin. Exclusion Criteria: * Teicoplanin was administered non-intravenously; * Teicoplanin was used for prophylactic purposes; * Patients without therapeutic concentration monitoring of teicoplanin; * Patients who die within 24 hours of the use of teicoplanin； * The blood concentrations of the patient was not approved by the quality control center.

Locations (1)

Shandong Provincial Qianfoshan Hospital

Ji'nan, Shandong, China

RECRUITING

Outcomes

Primary Outcomes

Plasma drug concentration

To detect the plasma concentrations of teicoplanin at therapeutic drug monitoring (TDM).

Time frame: Through study completion, an average of 14 days

Central Contacts

Wei Zhao, Ph.D

CONTACT

86053188383308 zhao4wei2@hotmail.com

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.